Anthranilic acid-based inhibitors of phosphodiesterase: design, synthesis, and bioactive evaluation. 2011

Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
Graduate Institute of Natural Products, Chang Gung University, Taoyuan, 33302, Taiwan.

Our previous studies identified two 2-benzoylaminobenzoate derivatives 1, which potently inhibited superoxide (O(2)˙(-)) generation induced by formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) in human neutrophils. In an attempt to improve their activities, a series of anthranilic acid derivatives were synthesized and their anti-inflammatory effects and underlying mechanisms were investigated in human neutrophils. Of these, compounds 17, 18, 46, 49, and 50 showed the most potent inhibitory effect on FMLP-induced release of O(2)˙(-) in human neutrophils with IC(50) values of 0.20, 0.16, 0.15, 0.06, and 0.29 μM, respectively. SAR analysis showed that the activities of most compounds were dependent on the ester chain length in the A ring. Conversely, a change in the linker between the A and B ring from amide to sulfonamide or N-methyl amide, as well as exchanges in the benzene rings (A or B rings) by isosteric replacements were unfavorable. Further studies indicated that inhibition of O(2)˙(-) production in human neutrophils by these anthranilic acids was associated with an elevation in cellular cAMP levels through the selective inhibition of phosphodiesterase 4. Compound 49 could be approved as a lead for the development of new drugs in the treatment of neutrophilic inflammatory diseases.

UI MeSH Term Description Entries
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D010727 Phosphoric Diester Hydrolases A class of enzymes that catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound. EC 3.1.4. Phosphodiesterase,Phosphodiesterases,Hydrolases, Phosphoric Diester
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D056945 Hep G2 Cells A human liver tumor cell line used to study a variety of liver-specific metabolic functions. Cell Line, Hep G2,Cell Line, Hepatoblastoma G2,Hep G2 Cell Line,HepG2 Cells,Hepatoblastoma G2 Cell Line,Cell, Hep G2,Cell, HepG2,Cells, Hep G2,Cells, HepG2,Hep G2 Cell,HepG2 Cell
D062367 ortho-Aminobenzoates Benzoic acids, salts, or esters that contain an amino group attached to carbon number 2 or 6 of the benzene ring structure. 2-Aminobenzoates,6-Aminobenzoates,Anthranilates,Anthranilic Acids,o-Aminobenzoates,o-Aminobenzoic Acids,ortho-Aminobenzoic Acids,6 Aminobenzoates,Acids, Anthranilic,Acids, o-Aminobenzoic,Acids, ortho-Aminobenzoic,o Aminobenzoates,o Aminobenzoic Acids,ortho Aminobenzoates,ortho Aminobenzoic Acids

Related Publications

Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
January 1999, Bioorganic & medicinal chemistry letters,
Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
January 2019, Bioorganic & medicinal chemistry letters,
Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
March 2012, Yao xue xue bao = Acta pharmaceutica Sinica,
Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
October 2004, Bioorganic & medicinal chemistry,
Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
August 2012, European journal of medicinal chemistry,
Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
April 2003, Bioorganic & medicinal chemistry letters,
Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
October 2012, Journal of medicinal chemistry,
Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
August 2023, Molecules (Basel, Switzerland),
Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
December 2021, Scientific reports,
Yih-Dih Cheng, and Tsong-Long Hwang, and Han-Hsiang Wang, and Tai-Long Pan, and Chin-Chung Wu, and Wen-Yi Chang, and Yi-Ting Liu, and Tzu-Chi Chu, and Pei-Wen Hsieh
December 2021, Chemical biology & drug design,
Copied contents to your clipboard!